EL7.AI
StocksMedium•10 November 2026•
1 min read

Tyra Biosciences Reports Q3 Results and Extends Cash Runway Through 2030

Key Facts

1Tyra Biosciences reported Q3 2026 financial results with cash and equivalents totaling $700.5 million.
2The company completed a $400 million financing, extending its cash runway through 2030.
3Initial Phase 2 SURF302 results for dabogratinib showed progress in patients with FGFR3-altered NMIBC.

Tyra Biosciences reported its Q3 2026 financial results, highlighting a cash position of $700.5 million. According to a company statement via PR Newswire, the firm completed a $400 million financing round, extending its operational cash runway through 2030. Clinical updates showed that initial Phase 2 SURF302 results for dabogratinib demonstrated progress in patients with FGFR3-altered non-muscle invasive bladder cancer (NMIBC).

TYRA closed at $22.3 on November 9, 2026, prior to the release of these quarterly updates. The company is currently advancing its broader pipeline, including TYRA-430 for hepatocellular carcinoma and TYRA-200 for metastatic intrahepatic cholangiocarcinoma, supported by the strengthened balance sheet intended to fund its precision medicine programs targeting FGFR biology.

Open on chart